InVivo Therapeutics Corp. added George Nolen, the former president and CEO of Siemens Corp., to its board of directors.
Nolen ran Siemens Corp., the U.S division of Siemens AG, from 2004 to August, 2009, when the 53-year-old retired after a 26-year stint. He currently sits on the board of the U.S. Chamber of Commerce and was named chair of the policy board at the Virginia Bioinformatics Institute.
InVivo CEO Frank Reynolds called Nolen a “mentor” from his own tenure at Siemens Corp., according to a press release.
Nolen was equally generous in his praise.
“I’m very excited to be part of something that will help so many people around the world and provide some relief for the enduring suffering caused by spinal cord injuries,” he said. “At Siemens I observed Frank’s success and I look forward to helping to guide InVivo’s success as we advance InVivo’s technologies to market.”
Last month, InVivo filed for an investigational device exemption from the Food & Drug Administration, seeking permission to begin human trials on the company’s treatment for spinal cord injury next year.